New Zealand markets open in 1 hour 36 minutes
  • NZX 50

    12,197.15
    +44.95 (+0.37%)
     
  • NZD/USD

    0.6308
    -0.0021 (-0.33%)
     
  • ALL ORDS

    7,745.90
    -25.90 (-0.33%)
     
  • OIL

    73.99
    +0.60 (+0.82%)
     
  • GOLD

    1,884.00
    +7.40 (+0.39%)
     

MTTI Receives Chinese Patent for EVATHERA Technology

WEST CHESTER, Pa., December 06, 2022--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of "Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents" follows issued patents in the US, Europe, Singapore, and Japan this past year.

EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide. EvaThera platform products were designed to bind to serum albumin, due to the Evans blue moiety, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical and reducing risk of renal injury vs. the current standard of care.

Our recent 3-year follow-up report on a 30-patient, ex-US, EBTATE study showed stable disease with progression-free survival of 43 months after three cycles of EBTATE. EBTATE treatment is effective and less toxic for neuroendocrine tumor patients. *

Chris Pak, MTTI’s President & CEO, commented, "This complements our IP portfolio, further protecting our EvaThera platform." He added, "We’re continuing to bolster our position in radiotheranostics with planned clinical trials of our two platform products in multiple indications."

About Molecular Targeting Technologies, Inc. (MTTI)

Molecular Targeting Technologies, Inc., is a privately held, rapidly growing, well financed, clinical-stage biotech company developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostics assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2023. For more information: www.evathera.com

See* below:

https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=36701

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005097/en/

Contacts

Chris Pak, Email: cpak@mtarget.com